BeOne Medicines AG (ONC) Stock Forecast & Price Target

ONC price $371.71 -1.65 -0.44%

Ticker
ONC
Price
$371.71
Change
-1.65 -0.44%
Market cap ?
$39.72B
P/E ?
5.04
Forward P/E ?
56.20
Dividend yield ?
0.00%
Beta ?
0.52
Sector
Healthcare
Industry
Biotechnology

Financials

2016201720182019202020212022202320242025
107000023838700019822000042821200030887400011762830001415921000245877900038102410005343033000

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid…

Forecast

Consensus Buy from 14 analysts. Average price target $396.89, +6.8% versus the current price. Low $340.00. High $451.00.

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Analysts have an average 12-month price target of $396.89 for BeOne Medicines AG (ONC), 6.7% above the current price of $372.11. Of 14 analysts covering the stock, 13 rate it Buy or Strong Buy, 1 Hold, and 0 Sell or Strong Sell, giving a consensus of Buy.

Forecasts are third-party estimates and often wrong. They are not investment advice.

ONC price target

12-month price target
Low$340.00
Average$396.89
High$451.00

The average is 6.7% above the current price of $372.11.

Is BeOne Medicines AG a buy or sell?

Of 14 analysts, 13 rate BeOne Medicines AG Buy or Strong Buy, 1 Hold, and 0 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.

BeOne Medicines AG earnings and revenue forecast

Analyst averages on file: 2026, EPS $6.61, revenue $6.49 billion. 2027, EPS $9.61, revenue $7.50 billion.

ONC score and fair value

The Stocklytics Score, when it is published for ONC, averages value, quality, and growth on a 0–100 scale. It is not a price target. Fair value is a separate estimate on the fair value tab.

ONC forecast FAQs

What is the ONC price target?

$396.89 average, with a published range of $340.00 to $451.00.

Is BeOne Medicines AG a buy or sell?

The consensus is Buy from 14 analysts. This is not a recommendation.

What is the BeOne Medicines AG stock forecast for 2026?

Analysts' average EPS estimate for 2026 on file is $6.61. The average revenue estimate is $6.49 billion.

What will ONC be worth in 2030?

No reliable forecast exists that far out.

When is BeOne Medicines AG's next earnings report?

The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.

Related: BeOne Medicines AG · Financials · Dividends · Compare · AI stocks

Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.

BeOne Medicines AG (ONC) Stock Forecast & Price Target

ONC$371.71-1.65 -0.44%

$39.72B

Market Cap

5.04

P/E

56.20

Forward P/E

—

Score

Price History